OBJECTIVE: The early diagnosis of nonfunctioning pituitary adenoma (NFPA) is difficult. The objective of this study was to find specific protein biomarkers to aid in the early detection of NFPA. METHODS: Serum samples from 34 patients with NFPA and 34 age-and sex-matched healthy control subjects were analysed using surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology. The spectra were generated, protein peak clustering was performed and classification analyses were carried out using a decision tree classification algorithm. RESULTS: Nine differentially expressed serum proteins were identified in the patients with NFPA compared with the control subjects. Both the sensitivity and specificity of the decision tree classification algorithm were 82.
Introduction
Pituitary adenomas are the most common tumours of the pituitary gland and comprise 10 -25% of all intracranial tumours. 1 -3 Systematic autopsy examinations have revealed that pituitary adenomas develop in 25% of the population. 4 Studies using computed tomography (CT) or magnetic resonance imaging (MRI) reveal that 20% of 'normal' pituitary glands harbour an incidental lesion. 5, 6 The prevalence of diagnosing a pituitary adenoma has increased over the past 20 years. 7 -9 Pituitary adenomas are classified as either being clinically functional adenomas or nonfunctioning pituitary adenomas (NFPAs). 10 The former group includes growth hormone (GH)secreting adenomas, prolactin (PRL)-secreting X Hu, P Zhang, A Shang et al. Differential serum protein levels in nonfunctioning pituitary adenoma adenomas, thyroid stimulating hormone (TSH)-secreting adenomas, adrenocorticotropic hormone (ACTH)-secreting adenomas and follicle stimulating hormone (FSH)secreting adenomas; while the remaining adenomas are clinically 'non-functioning'. 10 Nonfunctioning pituitary adenomas represent approximately 32% of pituitary adenomas and are characterized by the lack of hormone-related clinical syndrome as compared with functional adenomas. 10 Affected patients usually present with mass effects due to compression, including headache, visual-field defects or hypopituitarism. 8 NFPAs often secrete glycoprotein hormones and/or their free subunits. 11 Serum α-subunit levels and the response to thyrotropin releasing hormone (TRH) may be useful indicators for assessing the operative outcome in NFPA patients. 12 There appears to be a relationship between βluteinizing hormone (β-LH) levels, tumour size and surgical outcome, but this association is insufficient to allow the routine use of either basal or TRH-induced β-LH responses in the postsurgical follow-up of NFPA. 13 Early diagnosis and referral to centres with relevant expertise are important means of optimizing the short-and long-term outcomes of these patients. There is currently no tumour marker for NFPA and early diagnosis is difficult.
This study investigated whether there is a discriminatory proteomic pattern for patients with NFPA, based on peripheral serum proteomics analysis using surfaceenhanced laser desorption/ionization timeof-flight mass spectrometry (SELDI-TOF-MS). The study protocol complied with the Declaration of Helsinki and was approved by the Medical Ethics Committee of Beijing Normal University, Beijing, China prior to initiating recruitment. All participants provided written informed consent.
Patients and methods

STUDY POPULATION
BLOOD COLLECTION
Blood was collected from each study participant into 5 ml serum separator vacuum tubes (Sekisui PET vacuum blood collection tube -red; Sekisui Medical Technology (China), Beijing, China), kept at 4°C for 1 h and then centrifuged at 1610 g for 20 min at 4°C. The serum was divided into 200 µl aliquots and stored at −80°C.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
Pituitary samples were obtained from patients undergoing trans-sphenoidal surgery for pituitary adenoma. Tissues were immediately fixed in neutral buffered formalin (10%), processed, embedded in paraffin, cut into 4µm thick sections and stained for conventional light microscopy with haematoxylin and eosin. Adenomas were often spherical and X Hu, P Zhang, A Shang et al. Differential serum protein levels in nonfunctioning pituitary adenoma well-defined. The cells were usually larger than normal cells and were homogeneous, with large irregular nuclei and varying amounts of vacuolated cytoplasm.
Immunohistochemistry was performed on 4-µm thick paraffin-embedded sections of each tumour using the following pituitary hormone antibodies: rabbit antihuman GH (1 : 400 dilution); rabbit antihuman PRL (1 : 250 dilution); mouse antihuman ACTH (1 : 60 dilution); mouse antihuman TSH (1 : 50 dilution); mouse antihuman FSH (1 : 50 dilution); and mouse antihuman LH (1 : 50 dilution) (DAKO, Carpinteria, CA, USA). Slides were heated in 10 mM citrate buffer, pH 6.0 (Shanghai LiChen Chemical Co., Shanghai, China), in a pressure boiler for 3 min and then incubated with primary antibody (dilutions as above) for 30 min at room temperature. After washing three times with 0.01 mM phosphate-buffered saline (PBS), pH 7.4, slides were incubated in an optimally diluted cocktail of biotinylated goat antirabbit and goat antimouse secondary antibodies (DAKO) for 30 min at room temperature, and washed three times with PBS. The streptavidin-biotin-peroxidase technique with 3,3′-diaminobenzidine as chromogen (DAKO) was used to visualize immunostaining. Slides were examined via conventional light microscopy by two independent pathologists (Eclipse 80i; Nikon Corp., Sendai, Japan), and immunostaining was scored as 0 (negative), 1+ (10 -30% positive cells), 2+ (30 -50% positive cells) or 3+ (> 50% positive cells).
SELDI-TOF-MS PROTEIN PROFILING
Serum protein profiling analysis was performed on a ProteinChip ® CM10 array (weak cation exchanger) (Bio-Rad, Hercules, CA, USA). The CM10 protein chip arrays contain weak anionic carboxylated groups that interact with the positive charge on the surface of the analyte such as lysine, arginine or histidine. These arrays were used selectively to capture proteins with high isoelectric points and biomarkers that had positive charges on their surfaces.
Each array was pretreated with 5 µl of 10 mM hydrochloric acid at room temperature for 10 min. The chips were rinsed three times with 10 ml filtered distilled water in a conical tube and then placed in a bioprocessor (Bio-Rad), which allows for the application of larger volumes of serum to each chip array. The bioprocessor was washed with filtered distilled water and 200 µl of binding buffer (100 mM sodium acetate; pH 4.0) was added to each well, before shaking on a platform shaker at 250 rpm for 5 min at room temperature. The binding buffer was discarded by inverting the bioprocessor onto a paper towel, an additional 200 µl of binding buffer was added to each well and the bioprocessor was shaken again as before. A mixture of 3 ml of each serum sample and 6 ml of U9 buffer (9 M urea, 2% 3-[(3cholamidopropyl)dimethylammonio]-1-propane sulphonate, 50 mM Tris-HCl, 1% dithiothreitol; pH 9.0) was incubated for 30 min at 4°C, diluted with 111 ml binding buffer and 100 µl of this diluted sample was applied to each well. The bioprocessor was sealed and shaken on a platform shaker at 250 rpm for 35 min at room temperature. The samples were discarded and each well was washed three times with washing buffer (100 mM sodium acetate; pH 4.0). The chips were removed from the bioprocessor and air dried. Energy absorbing molecule (EAM) solution (0.5 µl of saturated sinapinic acid in 50% acetonitrile and 0.5% trifluoroacetic acid) was applied onto each chip array and allowed to air-dry before another 0.5 µl EAM application.
The protein mass spectral data were generated using a ProteinChip ® System 4000 X Hu, P Zhang, A Shang et al. Differential serum protein levels in nonfunctioning pituitary adenoma SELDI-TOF-MS mass spectrometer (Enterprise Edition; Bio-Rad) and an automated data collection protocol with the ProteinChip ® Data Manager Software 3.5 interface (Bio-Rad). The optimal laser intensity for spectra generation was predetermined to be 3500 nJ by manual laser shots. Data were collected between 0 and 70 kDa with the ion focus mass set to 8000 Da and the matrix attenuation to 1000 Da. After one initial warming shot, 50 points equally distributed over the chip spot surface were lasered 10 times for ionization of the proteins. Mass accuracy was calibrated externally using the ProteinChip ® All-in-One Peptide Standard (Bio-Rad).
PROTEIN PEAK DETECTION
All of the obtained spectra were internally mass-calibrated and normalized relative to the total ion current of a mass-to-charge ratio (m/z) of > 1000 to avoid signal interference from the EAM. Peak detection was performed using Biomarker Wizard software (Bio-Rad) under the following conditions: a signal-to-noise ratio of ≥ 5 for the first pass, a signal-to-noise ratio of 2 for the second pass, and presentation in at least 50% of spectra for identification.
DECISION TREE CLASSIFICATION ALGORITHM
Construction of the decision tree classification algorithm was performed by Ciphergen Biomarker Pattern software version 4.0 (Bio-Rad) using the optional Gini diversity index (the appropriate choice when the dependent variable is categorical in nature). The classification tree split the data into two nodes using one rule at a time in the form of peak intensity. The splitting decisions in this case were based on the normalized relative intensity levels of peaks from the SELDI protein expression profile. The process of splitting was continued until terminal nodes were created.
STATISTICAL ANALYSES
Sensitivity was calculated as the ratio of the number of correctly classified diseased samples to the total number of diseased samples. Specificity was calculated as the ratio of the number of correctly classified negative samples to the total number of true negative samples. Ten-fold cross-validation was used to assess accurately the goodnessof-fit, using Ciphergen Biomarker Pattern software. A P-value < 0.05 was considered statistically significant.
Results
The study included 34 Chinese patients diagnosed with NFPA (13 males, 21 females; mean ± SD age 43.7 ± 11.8 years; median 45.2 years; range 19 -66 years). The age and sex-matched healthy control group included 13 males and 21 females (mean ± SD age 43.7 ± 11.8 years; median 45.2 years; range 19 -66 years). The most common presenting symptoms in the NFPA group were visual (50.0%; 17/34) and headache (29.4%; 10/34).
The results of the protein peak clustering analysis (Biomarker Wizard plots) are shown in Fig. 1 . Nine differential protein levels were clearly identified in the sera from the NFPA group compared with the control group. Among these protein candidates, seven were upregulated and two were downregulated in the NFPA group compared with the control group (P < 0.05 for each protein peak; Table  1 , Fig. 2 ).
Immunohistochemical findings were available for 25 of the NFPA patients. Seven of these had the same immunohistochemical hormone secretion profile (PRL + , ACTH -, FSH -, GH -, TSHand LH -) and underwent independent protein peak clustering analysis X Hu, P Zhang, A Shang et al. Differential serum protein levels in nonfunctioning pituitary adenoma with their corresponding age and sexmatched healthy control subjects. Five differential protein levels were identified in these patients, all downregulated in the NFPA group compared with the control group (P < 0.05 for each protein peak; Table  2 , Fig. 3 ).
Application of the decision tree classification algorithm to protein peaks m/z 4310, 4669, 5341, 5456 and 5877 generated six terminal nodes (Fig. 4) . The relative intensity split criteria for nodes 1 -5 were: The sensitivity and a specificity of the decision tree classification algorithm were both calculated as 82.4% for NFPA using 10fold cross-validation.
Discussion
The early diagnosis of NFPA has always been a difficult challenge. Diagnosis currently relies on radiological features of CT or MRI, usually after the appearance of mass effects due to compression, but NFPA are sometimes only discovered as incidentalomas. 7, 8, 14 To reported. We believe, therefore, that the current study is the first serum proteomics analysis of patients with NFPA; 15 several potential biomarkers were identified and a decision tree classification for NFPA was constructed.
Some proteomic studies of NFPAs, using a targeted approach to undertake proteomic analysis based on the immunohisto -chemistry of pituitary adenoma tissues, have been reported. 14 Moreno et al. 3 investigated 11 NFPAs and eight normal pituitary glands, and proteomic analysis identified 21 upregulated and 29 downregulated proteins in the NFPAs. Proteins that were downregulated included the following: (i) neuroendocrine-related proteins, including somatotropin, secretagogin and µ-crystallin (iii) immunological regulation proteins and tumour-related antigen; (iv) cell proliferation, differentiation and apoptosis-related proteins; and (v) cell defence and stress resistance proteins. In addition, some metabolic enzyme-related proteins were upregulated in the NFPAs. 3 Zhan et al. 16 identified 251 differential protein spots in a set of NFPAs and prolactinomas compared with controls, of which 56 differentially regulated proteins (34 downregulated and 22 upregulated) were characterized by mass spectrometry. 16 These 56 differentially regulated proteins corresponded to the same functional categories as reported by Moreno et al., 3 with the addition of at least six isoforms of prolactin that were downregulated in NFPA and cell-signal proteins, some of which were downregulated and some were upregulated. The cell-signal proteins were those involved in complex biological roles involved in cell growth, proliferation, differentiation, apoptosis and death. 16 These studies provide an overview of the differential expression of proteins between NFPA and control samples based on known or postulated functions of the proteins.
These previous studies used whole control pituitary glands removed during autopsy as controls, and there are reservations regarding the use of autopsy samples for comparisons with fresh adenomatous tissues. 16 -18 Ideally, fresh control samples are needed for these types of studies, but the limited availability of pituitary material for research generally precludes the selection of an age or sex-matched control group that can provide fresh tissue samples. 18 The use of serum is a feasible alternative.
The technology of SELDI-TOF-MS offers opportunities to discover diagnostic markers for a number of diseases. 19, 20 It can rapidly provide protein profiles from a variety of biological samples with minimal requirements for purification and separation of proteins prior to mass spectrometry. Profiling studies using SELDI-TOF-MS have revealed that biological fluids contain many proteins of low molecular weight (< 15 kDa) that are not resolved on conventional twodimensional gels. 21, 22 SELDI-TOF-MS has been widely studied for the diagnosis of various cancers, such as lung, breast, prostate and colorectal cancer. 23 -28 The US Food and Drug Administration recently approved the first diagnostic tool (OVA1 ® ; Vermillion, Austin, TX, USA) developed from SELDI-TOF-MS proteomic research. 29 OVA1 ® uses a combination of five biomarkers for ovarian cancer diagnosis and demonstrates the potential of the technique. SELDI-TOF-MS technology does not, however, allow direct identification of the discriminatory proteins, which remains a problem that needs to be resolved for this technology. 1 The current study profiled serum proteins from patients with NFPA and from healthy age-and sex-matched control subjects using SELDI-TOF-MS technology. The use of serum, rather than pituitary glands that had been removed during autopsy, provided fresher samples and also allowed controls to be ageand sex-matched. Nine proteins were found to be significantly differentially expressed between the two study groups. A decision tree classification with four layers and six terminal nodes was constructed and was shown to have sensitivity and specificity of 82.4%. This decision tree classification was reflected through five molecular masses. No single biomarker was able to discriminate the patients with NFPA from the control group. The heterogeneity of NFPA might be one of the reasons why diagnosis is so difficult and the current NFPA classification does not reflect any molecular distinctions • Received for publication 7 September 2011 • Accepted subject to revision 29 September 2011
• Revised accepted 23 December 2011 Copyright © 2012 Field House Publishing LLP between the subtypes. 3 The NFPAs are monoclonal in origin 11 and are classified into three subtypes on the basis of immunohistochemistry: (i) gonadotroph adenomas, containing the β-subunit of LH and FSH either singly or in combination with the α-subunit; (ii) null cell adenomas, which are negative for all hormones except cases with isolated α-subunit positivity; and (iii) silent (nongonadotroph) adenomas, containing PRL, GH or ACTH but not showing any clinical features of hormone secretion. 30 In the current study, seven NFPAs positive only for PRL were selected and compared with their age-and sex-matched controls to avoid the problem of heterogeneity. Compared with the analysis of the entire study population, this subgroup analysis demonstrated a clearer difference between the two groups. It is not possible to draw any statistically significant conclusion from these data, due to the small number of subjects, but the findings provide useful information about potential biomarkers that could be used in the diagnosis of NFPA. The NFPA subtype might be reflected in serum protein profiling, which may lead to more detailed subdivisions being identified and the improved diagnosis and treatment of NFPA. If more NFPAs with the same immunohistochemical phenotype could be analysed, then more specific and powerful biomarkers might be identified in the future.
In conclusion, the current study provides the first serum proteomics analysis of patients with NFPA and shows that the use of SELDI-TOF-MS technology combined with data mining tools can be applied to the diagnosis of NFPA. This technology might also provide the means for population screening for NFPA in the future. Larger studies are needed to improve the sensitivity and specificity of this potential diagnostic tool.
